China Pharma Financials
China Pharma (CPHI) reported $4.1M in revenue for fiscal year 2025, down 8.5% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Persistent gross losses, not financing costs, dominate the model, while a temporary cash-flow improvement coexists with worsening short-term liquidity.
FY2025 operating cash flow turned positive at$148K while net loss remained-$3.2M , so the cash result does not represent earnings recovery. Because capital spending was only$59K , nearly all operating cash flow passed through to free cash flow; the shift from FY2024’s negative cash generation therefore reflects working-capital or noncash effects rather than a profitable operating engine.
The gross loss narrowed from
Debt-to-equity fell to 0.4x, but short-term coverage deteriorated: the current ratio reached 0.3x. The balance-sheet expansion is therefore not translating into liquidity, with cash falling from
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of China Pharma's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
China Pharma scores 0.29, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($38.9M) relative to total liabilities ($8.3M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
China Pharma passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.
China Pharma reported a net loss of $3.2M while generating $148K in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
China Pharma reported an operating loss of $3.2M against $27K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
China Pharma generated $4.1M in revenue in fiscal year 2025. This represents a decrease of 8.5% from the prior year.
China Pharma's EBITDA was -$1.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 11.9% from the prior year.
China Pharma reported -$3.2M in net income in fiscal year 2025. This represents an increase of 32.7% from the prior year.
Cash & Balance Sheet
China Pharma generated $89K in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 120.0% from the prior year.
China Pharma held $345K in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
China Pharma's gross margin was -3.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 40.7 percentage points from the prior year.
China Pharma's operating margin was -78.2% in fiscal year 2025, reflecting core business profitability. No change is given against fiscal year 2024: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
China Pharma's net profit margin was -76.9% in fiscal year 2025, showing the share of revenue converted to profit. No change is given against fiscal year 2024: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
China Pharma's ROE was -14.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 47.1 percentage points from the prior year.
Capital Allocation
China Pharma invested $281K in research and development in fiscal year 2025. This represents a decrease of 1.1% from the prior year.
China Pharma invested $59K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 54.4% from the prior year.
Not reported for fiscal year 2025.
CPHI Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $948K-3.6% | $984K-19.8% | $1.2M+62.1% | $756K-26.3% | $1.0M-9.7% | $1.1M+0.2% | $1.1M+3.1% | $1.1M |
| Cost of Revenue | $865K+23.9% | $698K-35.1% | $1.1M+31.8% | $816K-26.7% | $1.1M-12.5% | $1.3M-1.7% | $1.3M-20.1% | $1.6M |
| Gross Profit | $84K-70.7% | $285K+89.3% | $151K+352.7% | -$60K+31.4% | -$87K+36.1% | -$136K+15.3% | -$161K+69.1% | -$520K |
| R&D Expenses | $19K-77.2% | $84K-55.9% | $190K+371.3% | $40K+92.4% | $21K-29.2% | $30K+5309.0% | $547-99.4% | $88K |
| SG&A Expenses | $1.4M+12.3% | $1.2M+13.7% | $1.1M+153.9% | $425K-3.6% | $441K-13.1% | $507K-41.0% | $859K+149.1% | $345K |
| Operating Income | -$1.4M-28.2% | -$1.1M+6.9% | -$1.2M-91.1% | -$628K+3.7% | -$652K+14.0% | -$759K+36.6% | -$1.2M-10.2% | -$1.1M |
| Interest Expense | $9K+2.4% | $9K+31.4% | $7K+1.7% | $7K+0.4% | $7K-0.2% | $7K-0.2% | $7K-0.6% | $7K |
| Net Income | -$1.5M-27.6% | -$1.1M+6.5% | -$1.2M-87.6% | -$651K-23.3% | -$528K+32.7% | -$786K+35.8% | -$1.2M-9.5% | -$1.1M |
| EPS (Diluted) | -$0.040.0% | -$0.04 | -$0.17 | -$0.17-6.3% | -$0.16+33.3% | -$0.24 | -$0.04 | -$0.65 |
Not reported in any period shown, so not listed: Income Tax.
CPHI Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $44.7M-1.0% | $45.1M+45.6% | $31.0M+96.1% | $15.8M+14.8% | $13.8M-3.2% | $14.2M-4.5% | $14.9M+10.6% | $13.5M |
| Current Assets | $2.0M+0.2% | $2.0M-14.6% | $2.3M+0.7% | $2.3M-13.8% | $2.7M-5.3% | $2.9M-12.8% | $3.3M-12.5% | $3.7M |
| Cash & Equivalents | $305K+81.0% | $168K-51.2% | $345K+29.0% | $268K-55.4% | $600K+50.0% | $400K-36.2% | $627K-10.4% | $700K |
| Inventory | $1.4M-9.1% | $1.5M-7.6% | $1.6M-1.7% | $1.6M-1.7% | $1.7M-15.2% | $2.0M-12.7% | $2.3M-9.3% | $2.5M |
| Accounts Receivable | $182K-7.5% | $196K-18.7% | $241K+7.5% | $225K-16.4% | $269K-18.3% | $329K+41.7% | $232K-30.4% | $333K |
| Total Liabilities | $8.5M+5.0% | $8.1M-1.7% | $8.3M+10.3% | $7.5M+2.5% | $7.3M+0.8% | $7.2M+1.5% | $7.1M+2.9% | $6.9M |
| Current Liabilities | $7.7M+5.7% | $7.3M-1.8% | $7.4M+11.7% | $6.6M+26.1% | $5.3M+2.5% | $5.1M+2.1% | $5.0M+5.4% | $4.8M |
| Total Equity | $36.2M-2.3% | $37.0M+62.8% | $22.7M+173.5% | $8.3M+28.7% | $6.5M-7.3% | $7.0M-10.0% | $7.7M+18.7% | $6.5M |
| Retained Earnings | -$49.8M-3.0% | -$48.4M-2.4% | -$47.2M-2.7% | -$46.0M-1.4% | -$45.3M-1.2% | -$44.8M-1.8% | -$44.0M-2.9% | -$42.8M |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
CPHI Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$33K+40.6% | -$55K-136.4% | $152K+174.4% | -$204K-174.5% | $274K+472.3% | -$74K-124.7% | $299K+736.3% | -$47K |
| Capital Expenditures | N/A | N/A | $454-25.7% | $611+840.0% | -$65-99.9% | $58K+198.4% | $20K+112.0% | -$9K |
| Free Cash Flow | N/A | N/A | $152K+173.9% | -$205K-174.7% | $274K+307.8% | -$132K-147.3% | $279K+597.1% | -$56K |
| Investing Cash Flow | N/A | N/A | -$6K+92.1% | -$73K-112753.8% | $65+100.1% | -$58K+78.6% | -$273K-3059.3% | $9K |
| Financing Cash Flow | $120K+251.4% | -$79K-9.3% | -$73K+40.6% | -$122K-445.6% | -$22K+70.8% | -$77K-41.4% | -$54K-894.0% | $7K |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
CPHI Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 8.8%-20.2pp | 29.0%+16.7pp | 12.3%+20.2pp | -7.9%+0.6pp | -8.5%+3.5pp | -12.0%+2.2pp | -14.2%+33.1pp | -47.2% |
| Operating Margin | -151.0% | -113.6% | -97.9%-14.8pp | -83.1%-19.5pp | -63.6%+3.2pp | -66.8% | -105.5% | -98.7% |
| Net Margin | -153.8% | -116.2% | -99.7%-13.5pp | -86.2%-34.6pp | -51.5%+17.6pp | -69.1% | -108.0% | -101.6% |
| Return on Equity | -4.0%-0.9pp | -3.1%+2.3pp | -5.4%+2.5pp | -7.8%+0.3pp | -8.2%+3.1pp | -11.3%+4.5pp | -15.8%+1.3pp | -17.1% |
| Return on Assets | -3.3%-0.7pp | -2.5%+1.4pp | -3.9%+0.2pp | -4.1%-0.3pp | -3.8%+1.7pp | -5.5%+2.7pp | -8.2%+0.1pp | -8.3% |
| Current Ratio | 0.260.0x | 0.280.0x | 0.320.0x | 0.35-0.2x | 0.510.0x | 0.56-0.1x | 0.65-0.1x | 0.79 |
| Debt-to-Equity | 0.240.0x | 0.22-0.1x | 0.36-0.5x | 0.90-0.2x | 1.13+0.1x | 1.04+0.1x | 0.92-0.1x | 1.06 |
| FCF Margin | N/A | N/A | 12.4%+39.5pp | -27.1%-53.8pp | 26.7%+38.4pp | -11.6%-36.2pp | 24.6%+29.7pp | -5.1% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Note: The current ratio is below 1.0 (0.32), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Where China Pharma Ranks
Frequently Asked Questions
What is China Pharma's annual revenue?
China Pharma (CPHI) reported $4.1M in total revenue for fiscal year 2025. This represents a -8.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is China Pharma's revenue growing?
China Pharma (CPHI) revenue declined by 8.5% year-over-year, from $4.5M to $4.1M in fiscal year 2025.
Is China Pharma profitable?
No, China Pharma (CPHI) reported a net income of -$3.2M in fiscal year 2025, with a net profit margin of -76.9%.
What is China Pharma's EBITDA?
China Pharma (CPHI) had EBITDA of -$1.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is China Pharma's gross margin?
China Pharma (CPHI) had a gross margin of -3.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is China Pharma's operating margin?
China Pharma (CPHI) had an operating margin of -78.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is China Pharma's net profit margin?
China Pharma (CPHI) had a net profit margin of -76.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is China Pharma's return on equity (ROE)?
China Pharma (CPHI) has a return on equity of -14.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is China Pharma's free cash flow?
China Pharma (CPHI) generated $89K in free cash flow during fiscal year 2025. This represents a 120.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is China Pharma's operating cash flow?
China Pharma (CPHI) generated $148K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are China Pharma's total assets?
China Pharma (CPHI) had $31.0M in total assets as of fiscal year 2025, including both current and long-term assets.
What are China Pharma's capital expenditures?
China Pharma (CPHI) invested $59K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does China Pharma spend on research and development?
China Pharma (CPHI) invested $281K in research and development during fiscal year 2025.
What is China Pharma's current ratio?
China Pharma (CPHI) had a current ratio of 0.32 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is China Pharma's debt-to-equity ratio?
China Pharma (CPHI) had a debt-to-equity ratio of 0.36 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is China Pharma's return on assets (ROA)?
China Pharma (CPHI) had a return on assets of -10.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is China Pharma's Altman Z-Score?
China Pharma (CPHI) has an Altman Z-Score of 0.29, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is China Pharma's Piotroski F-Score?
China Pharma (CPHI) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are China Pharma's earnings high quality?
China Pharma (CPHI) reported a net loss of $3.2M while generating $148K in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can China Pharma cover its interest payments?
China Pharma (CPHI) reported an operating loss of $3.2M against $27K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is China Pharma?
China Pharma (CPHI) scores 40 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.